Therapeutic actions of 5‐HT3R antagonists for POI

E-ISSN： 1476-5381|172|4|1136-1147

ISSN： 0007-1188

Source： BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.172, Iss.4, 2015-02, pp. : 1136-1147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-HT₃-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 97-109

Karger

Access to resources Recommend Favorite

Chemotherapy-Induced Emesis in Elderly Cancer Patients: The Role of 5-HT₃-Receptor Antagonists in the First 24 Hours

Gerontology, Vol. 51, Iss. 5, 2005-08 ,pp. : 287-296

Karger

Access to resources Recommend Favorite

Aprepitant as Salvage Therapy in Patients with Chemotherapy-Induced Nausea and Emesis Refractory to Prophylaxis with 5-HT₃ Antagonists and Dexamethasone

Oncology Research and Treatment, Vol. 29, Iss. 12, 2006-12 ,pp. : 557-561

Karger

Access to resources Recommend Favorite

Haloperidol Versus 5‐HT₃ Receptor Antagonists for Postoperative Vomiting and QTc Prolongation: A Noninferiority Meta‐Analysis and Trial Sequential Analysis of Randomized Controlled Trials

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 2, 2018-02 ,pp. : 131-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic Relevance of the Allosteric Modulation of the 5-HT Transporter

Current Signal Transduction Therapy, Vol. 4, Iss. 2, 2009-01 ,pp. : 82-87

Bentham Science Publishers

Access to resources Recommend Favorite